PB0024 - The efficacy and safety of low dose aspirin for recurrent arterial events prevention in Essential Thrombocythemia in: A systematic review

Sunday, June 23, 2024

13:45 – 14:45 ICT

Room: Exhibition Hall

Presenting Author(s)

AK

Andree Kurniawan, MD, PhD

Lecturer
Faculty of Medicine, Pelita Harapan University
Jakarta, Jakarta Raya, Indonesia

Co-Author(s)

Dimas Priantono, MD

Haematology and Medical Oncology Trainee
Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Jakarta Pusat, Jakarta Raya, Indonesia
Ardhi Rahman Ahani, MD

Lecturer
Faculty of Medicine, Universitas Indonesia, Jl Dr Cipto Mangunkusumo Hospital
Jakarta, Jakarta Raya, Indonesia
CS

Chandra Sari

Trainee
Faculty of Medicine, Universitas Indonesia, Jl Dr Cipto Mangunkusumo Hospital
Jakarta, Jakarta Raya, Indonesia
DA

Devi Astri Rivera Amelia

Trainee
Faculty of Medicine, Universitas Indonesia, Jl Dr Cipto Mangunkusumo Hospital
Jakarta, Jakarta Raya, Indonesia
DD

Deden Djatnika

Trainee
Faculty of Medicine, Universitas Indonesia, Jl Dr Cipto Mangunkusumo Hospital
Jakarta, Jakarta Raya, Indonesia
MN

Muhammad Arman Nasution

Trainee
Faculty of Medicine, Universitas Indonesia, Jl Dr Cipto Mangunkusumo Hospital
Jakarta, Jakarta Raya, Indonesia
BS

Brigitta Isabella Bunga Sutrisno

student
Faculty of Medicine, Pelita Harapan University
Tangerang, Banten, Indonesia
IA

Irene Adelia

MD
Siloam Hospital Lippo Karawaci
Jakarta Barat, Jakarta Raya, Indonesia
Mo

Mathhea Thessa ohira

Trainee
Faculty of Medicine
Tangerang, Banten, Indonesia

Background: Essential thrombocythemia (ET) is a chronic myeloid malignancy characterized by thrombocytosis, characterized by somatic mutation such as JAK2, CALR, or MPL. Low dose aspirin once daily is recommended treatment to prevent vascular event in all ET risk categories except in low risk disease. However, there is limited data regarding the role of low dose aspirin to prevent arterial events in recurrent settings.

Aims: To know the efficacy and safety of low dose aspirin in Essential thrombocytosis for prevention of recurrent arterial events

Methods: We performed a systematic literature search from PubMed and Cochrane with the search terms: ‘Essential thrombocytosis’ AND ‘Aspirin’ AND recurrent ‘Stroke’ OR ‘Myocardial infarct’ OR ‘PAD’. The type of study designs included in the review were Randomized Control Trial (RCT), Cohort, and Clinical Trial. The Newcastle Ottawa Scale (NOS) and the Jadad Scale were used as the basis for this review.

Results: Through the inclusion criteria, 4 articles were obtained. It was found that low dose of aspirin seems to be effective in preventing recurrent thrombotic events. Low dose aspirin could reduce the number of arterial thrombosis without increasing bleeding complications in patients with elevated platelet count and common atherosclerotic risk factors. (HR= 0.97 (95% CI 0.62–1.52)
Another study also showed that preemptive addition aspirin to hydroxychloroquine did not reduce the risk of vascular events ET patients ages 40 to 59 years who lacked high-risk factors for thrombosis or extreme thrombocytosis. Two studies showed good quality and the others were fair.

Conclusion(s): There is limited good evidence regarding the prevention of recurrent arterial events in essential thrombocytosis. Clinical stratification of thrombotic risk in essential thrombocytosis is needed to tailor the most optimal therapy in ET.